Home › Gastrointestinal Cancers › NCT05375643
SURGE: Supporting Utility and Representation in Genomics-based Cancer Trial Enrollment (Intervention)
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Adult (age 18 years or older) * Scheduled for a new patient consultation * Suspected or confirmed advanced malignancy (requiring active treatment) * DFCI patient at Longwood/Chestnut Hill, DFCI satellite at BMC-Brighton (formerly St. Elizabeth's Medical Center), DFCI satellite at Foxborough, or DFCI satellite at Merrimack Valley Exclusion Criteria: * Malignancy or former malignancy that requires only surveillance * Not continuing care at a participating DFCI site * Speaks a language other than English, Spanish, Haitian Creole, Russian, Portuguese, Arabic, or Traditional Chinese * Unable to provide consent
About the study
SURGE aims to increase representation in clinical trial enrollment by addressing barriers to genomic testing, which is increasingly needed to assess precision clinical trial eligibility and access standard precision therapies. The study is an interventional pilot meant primarily to assess the feasibility of the intervention. The intervention is comprised of a patient navigator, text message questionnaire, and informational video.
What is being tested
- SURGE (behavioral)
Sponsor: Nadine Jackson, MD, MPH · Participants: 210 · Started: Apr 3, 2023
Contact the study team
- Nadine A Jackson, MD MPH · Phone: (617) 632-6729
- Nadine J McCleary, MD MPH · Phone: (617) 632-6729
Official record on ClinicalTrials.gov — NCT05375643
Locations in the U.S.
| Massachusetts | Dana Farber Cancer Institute, Boston Dana-Farber Cancer Institute at St. Elizabeth's Medical Center, Brighton Dana-Farber Cancer Instiute - Merrimack Valley, Methuen (Not yet recruiting) |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.